- Data obtained from the State Health Information Network for New York (SHIN-NY) and from hospital data requests

- Laboratory results from New York State Department of Health 

- Abstraction from hospital electronic medical records done by a team of nurses, doctors, and epidemiologists to record outcomes, illness and treatment details


Data collection for evaluating outcomes in hospitalized COVID-19 patients in New York City given Azithromycin, Hydrochloroquine, or a combination

- Took a random sample of eligible patients, stratified by hospital

- 25 hospitals in New York City metropolitan area were selected by having a “high-volume” of COVID-19 cases, defined as 45 discharges during the sampling period

- Patients were eligible if admitted to one of these hospitals for at least 24 hours between March 15 and March 28, 2020 and tested positive for SARS-CoV-2

Sample selection for evaluating outcomes in hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination

- Patient demographics
- Preexisting conditions
- Initial vital signs
- Laboratory test results within 24 hours of admission
- Chest imaging
- Racial and ethnic classification 


Data/variables of interest for evaluating outcomes in hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination

- Sample selection
- Data collection
- Data/variables of interest
- Statistical analysis

University of Michigan - Ann Arbor

"A greater proportion of patients receiving hydroxychloroquine + azithromycin experienced cardiac arrest (15.5%) and abnormal ECG findings (27.1%), as did those in the hydroxychloroquine alone group (13.7% and 27.3, respectively), compared with azithromycin alone (6.2% and 16.1%, respectively) and neither drug (6.8% and 14.0%, respectively)."

Proportion of abnormal ECG findings  in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine  and Hydroxychloroquine

Methods for determining odds of abnormal ECG readings amongst hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination

Learn Before

Learn After